RemedyMD’s solution shifts focus towards research based on more comprehensive scientific evidence

Sandy, UT -- (SBWIRE) -- 01/25/2010 -- RemedyMD , the leading provider of Disease Registry software, today announced the first nationwide Multi-level Intervention Registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/multi_intervention.html

RemedyMD's multi-level intervention registry compares the effectiveness of interventions:
community-based multi-level interventions
simple health education
usual care
to reduce health disparities in cardiovascular disease, diabetes, cancer, musculoskeletal diseases, and birth outcomes. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new multi-intervention registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to this research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of interventional researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/multi_intervention.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html
Ways to Leverage Pediatric Diabetes Registry: http://www.remedymd.com/cer100/multi_intervention.html
Comparative Effectiveness Research: http://www.remedymd.com/cer_home.html
Disease Registry Software: http://www.remedymd.com/registries_home.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 12/21/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide chronic disease registry for at-risk populations (such as urban poor and American Indians) to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/chronic_disease.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's chronic disease registry for at-risk populations compares the effectiveness of various strategies (e.g., clinical interventions, selected social interventions [such as improving the built environment in communities and making healthy foods more available], combined clinical and social interventions) to prevent:

* Obesity
* Hypertension
* Diabetes

and heart disease in at-risk populations such as the urban poor and American Indians. The new registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's chronic disease registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to chronic disease research for at-risk populations, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of chronic disease researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/chronic_disease.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html
Ways to Leverage Chronic Disease Registry: http://www.remedymd.com/CER100/chronic_disease.html

Comparative Effectiveness Research:
http://www.remedymd.com/cer_home.html

Disease Registry Software:
http://www.remedymd.com/registries_home.html

Institute of Medicine's Top 100 Priorities for CER:
http://www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and disease registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 12/11/2009 -- RemedyMD , the leading provider of disease registry software, today announced the first nationwide osteoporosis registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/osteo_exercise.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's Osteo–Exercise registry compares the long-term effectiveness of weight-bearing exercise and bisphosphonates in preventing hip and vertebral fractures in older women with Osteopenia and/or Osteoporosis. The new registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's Osteo-Exercise registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to osteopenia and osteoporosis research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of osteoporosis researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/osteo_exercise.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html

Ways to Leverage Osteo-Exercise Registry: http://www.remedymd.com/CER100/osteo_exercise.html

Comparative Effectiveness Research:
http://www.remedymd.com/cer_home.html
Disease Registry Software:
http://www.remedymd.com/registries_home.html
Institute of Medicine's Top 100 Priorities for CER:
http://www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and disease registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution aims to solve $174 billion problem by shifting focus towards research based on more comprehensive scientific evidence

Sandy, UT -- (SBWIRE) -- 12/09/2009 -- RemedyMD, the leading provider of Disease Registry software, today announced the first nationwide Pediatric Diabetes Registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/pediatric_diabetes.html

RemedyMD's pediatric diabetes registry tracks patient outcomes over time including changes in HgA1c, LDL cholesterol and insulin levels. Researchers and clinicians can also track HgA1c by medication or medication class and easily generate reports showing results by multiple demographic or clinical indicators such as:

* Age
* Gender
* Ethnicity
* Insurance type

The new registry contains 1,500+ pediatric diabetes-specific fields for physicians, nurses, social workers, and dietitians to support all elements of pediatric diabetes research. Additionally, the registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new pediatric diabetes registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to pediatric diabetes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of pediatric diabetes researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/pediatric_diabetes.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html
Ways to Leverage Pediatric Diabetes Registry: http://www.remedymd.com/cer100/pediatric_diabetes.html
Comparative Effectiveness Research: http://www.remedymd.com/cer_home.html
Disease Registry Software: http://www.remedymd.com/registries_home.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 12/09/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide abdominal surgery registry to help clinicians and researchers identify which surgical interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/abdominal_surg.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's abdominal surgery registry compares the effectiveness of minimally invasive abdominal surgery and open surgical procedures on postoperative infections, pain management, and recuperative requirements. The new registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's abdominal surgery registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to surgical outcomes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of abdominal surgery researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/abdominal_surg.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html
Ways to leverage abdominal surgery registry: http://www.remedymd.com/CER100/abdominal_surg.html
Comparative Effectiveness Research:
http://www.remedymd.com/cer_home.html

Disease Registry Software:
http://www.remedymd.com/registries_home.html
Institute of Medicine's Top 100 Priorities for CER:
http://www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and disease registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Sandy, UT -- (SBWIRE) -- 12/03/2009 -- RemedyMD , the leading provider of disease registry software, today announced the first nationwide cervical spondylotic myelopathy (CSM) registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/csm.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's cervical spondylotic myelopathy registry is a prospective registry that compares the effectiveness of surgical and nonsurgical strategies for treating cervical spondylotic myelopathy (CSM) in patients with different characteristics to help researchers identify predictors of improved patient outcomes.

The cervical spondylotic myelopathy registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new CSM registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to cervical spondylotic myelopathy research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of CSM researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/csm.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html
Ways to leverage CSM registry: http://www.remedymd.com/CER100/csm.html

Comparative Effectiveness Research:
http://www.remedymd.com/cer_home.html

Disease Registry Software:
http://www.remedymd.com/registries_home.html

Institute of Medicine's Top 100 Priorities for CER:
http://www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and disease registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT-- (SBWIRE) -- 11/20/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide comprehensive obesity registry for bariatrics. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/comp_obesity.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's comprehensive obesity registry for bariatrics compares the effectiveness of many treatment strategies including:
various bariatric surgery procedure, behavioral interventions, and pharmacologic treatment on the resolution of obesity-related outcomes such as:
Diabetes
Hypertension
Musculoskeletal disorders

The registry provides detailed data collected from over 100 practices that can be used in addressing many pressing questions such as; what is the effect of each type of bariatric surgery on a patient's Hga1c levels, levels of insulin required, and weight reduction over a 3 year period. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new obesity registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to bariatric research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of bariatric researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/comp_obesity.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit.html

Ways to leverage Comprehensive Obesity Registry for Bariatrics: http://www.remedymd.com/cer100/comp_obesity.html

Comparative Effectiveness Research: http://www.remedymd.com/cer_home.html

Disease Registry Software: http://www.remedymd.com/registries_home.html

Institute of Medicine's Top 100 Priorities for CER: http://www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 11/18/2009 -- RemedyMD , the leading provider of disease registry software, today announced the first nationwide clinical registry for remote monitoring technologies. The new registry was developed to help clinicians and researchers identify which remote patient monitoring and management technologies are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/remote_tech.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's remote monitoring technologies registry compares the effectiveness of new remote patient monitoring and management methodologies including: telemedicine, internet, and remote sensing technologies on:

* Resource utilization
* Workforce needs
* Net health care expenditures
* Requirements for large-scale deployment

and traditional "in-person" care in managing chronic disease, especially in rural settings. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new remote monitoring technologies registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to medical device research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective remote monitoring options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of medical device researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/remote_tech.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit
Ways to leverage Remote Monitoring Technologies Registry: http://www.remedymd.com/cer100/remote_tech
Comparative Effectiveness Research: http://www.remedymd.com/cer_home
Disease Registry Software: http://www.remedymd.com/registries_home
Institute of Medicine's Top 100 Priorities for CER: http://www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 11/17/2009 -- RemedyMD , the leading provider of Patient registry software, today announced the first nationwide Type 2 Diabetes Registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/type2.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's type 2 diabetes registry includes long term cost and compares medical management with education, support groups and behavior modification

The type 2 diabetes registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new type 2 diabetes registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to type 2 diabetes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of type2 diabetes researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/type2.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit.html
Ways to leverage type 2 diabetes registry: www.remedymd.com/CER100/type2.html
Comparative Effectiveness Research:
http://www.remedymd.com/cer_home.html
Disease Registry Software:
http://www.remedymd.com/registries_home.html
Institute of Medicine's Top 100 Priorities for CER:
http://www.remedymd.com/cer_kit.html

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, patient, and Disease Registry Software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 11/16/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide renal replacement therapies registry. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/renal_therapies.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's renal therapies registry compares the effectiveness (including survival, hospitalization, quality of life, and costs) of renal replacement therapies including:

* Daily home hemodialysis
* Intermittent home hemodialysis
* Conventional in-center dialysis
* Continuous ambulatory peritoneal dialysis
* Renal transplantation

for patients of different ages, races, and ethnicities. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new renal therapies registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to kidney research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of kidney researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/renal_therapies.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: http://www.remedymd.com/cer_kit

Ways to leverage Renal Therapies Registry: http://www.remedymd.com/cer100/renal therapies

Comparative Effectiveness Research: http://www.remedymd.com/cer_home

Disease Registry Software: http://www.remedymd.com/registries_home

Institute of Medicine's Top 100 Priorities for CER: http://www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 11/12/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide vision impairment registry for diabetics. The new registry was developed to help clinicians and researchers identify which interventions are most appropriate for specific patient populations.

Details about the registry: http://www.remedymd.com/cer100/diabetes_vision.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's vision impairment registry for diabetics compares the effectiveness of different treatment options including:
* Laser therapy
* Intravitreal steroids
* Anti-vascular endothelial growth factor (anti-VEGF) for diabetic retinopathy
* Macular degeneration
* Retinal vein occlusion
The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when you view and report across all data types at the same time, you discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new vision impairment registry for diabetics includes a comprehensive set of electronic data collection (EDC) forms that are specific to diabetes research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of diabetes researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: http://www.remedymd.com/cer100/diabetes_vision.html

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit
Ways to leverage Vision Impairment Registry for Diabetics: www.remedymd.com/cer100/diabetes_vision
Comparative Effectiveness Research: www.remedymd.com/cer_home
Disease Registry Software: www.remedymd.com/registries_home
Institute of Medicine's Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit http://www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm

RemedyMD’s solution addresses Institute of Medicine’s top 100 priorities and shifts focus towards research based on more comprehensive scientific evidence

Salt Lake City, UT -- (SBWIRE) -- 11/03/2009 -- RemedyMD, the leading provider of disease registry software, today announced the first nationwide cervical pain registry to help clinicians and researchers identify which interventions are most appropriate for specific patient populations

Details about the registry: www.remedymd.com/cer100/cerv.html

Aligned with the Institute of Medicine's Top 100 Priorities for Comparative Effectiveness Research (CER), RemedyMD's cervical pain registry tracks the effectiveness of combining physical therapy with various treatment strategies including:

*Artificial cervical discs
*Spinal fusion
*Pharmacologic treatment

for cervical disc and neck pain. The registry includes all of the applications, data infrastructure, and tools that clinicians and researchers need to gather, synthesize and analyze both phenotypic and genotypic data simultaneously.

"Our experience has shown when researchers view and report across all data types at the same time, they discover patterns and associations that are indistinguishable using traditional methodologies" said Gary D. Kennedy, Founder and CEO of RemedyMD.

RemedyMD's new cervical pain registry includes a comprehensive set of electronic data collection (EDC) forms that are specific to cervical pain research, ad hoc reporting capability, and pattern recognition tools that assist users in identifying the most effective treatment options.

In support of this initiative RemedyMD is seeking additional partners who have existing data that addresses the specific needs of cervical pain researchers. All institutions involved in comparative effectiveness research that are planning on submitting grant proposals for AHRQ funding are invited to visit: www.remedymd.com/cer100/cerv

RemedyMD Resources:
Resource Kit for Comparative Effectiveness Research: www.remedymd.com/cer_kit
Ways to leverage Cervical Pain Registry: www.remedymd.com/cer100/cerv
Comparative Effectiveness Research: www.remedymd.com/cer_home
Disease Registry Software: www.remedymd.com/registries_home
Institute of Medicine's Top 100 Priorities for CER: www.remedymd.com/cer_kit

About RemedyMD
RemedyMD® is the leading provider of specialized software applications, tools, and data necessary for comparative effectiveness research with more than 100 pre-built clinical, disease, and patient registry software applications. RemedyMD solutions are personalized to the institution, the clinical specialty, and to the individual provider's preferences enabling researchers to identify new patterns, facilitate new discoveries, and improve medical outcomes. For more information, visit www.RemedyMD.com.

Press Contact:
Lane Peterson
RemedyMD
SALT LAKE CITY, US
801.733.3383
lpeterson@remedymd.com
http://www.RemedyMD.com

For more information on this press release visit: http://www.releasewire.com/press-releases/release-3.htm